These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32900573)

  • 1. A monocyte-keratinocyte-derived co-culture assay accurately identifies efficacies of BET inhibitors as therapeutic candidates for psoriasiform dermatitis.
    Wu X; Shi Z; Hsu DK; Chong J; Huynh M; Mendoza L; Yamada D; Hwang ST
    J Dermatol Sci; 2020 Oct; 100(1):31-38. PubMed ID: 32900573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways.
    Xu J; Duan X; Hu F; Poorun D; Liu X; Wang X; Zhang S; Gan L; He M; Zhu K; Ming Z; Chen H
    J Dermatol Sci; 2018 Feb; 89(2):127-135. PubMed ID: 29137840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facile skin targeting of a thalidomide analog containing benzyl chloride moiety alleviates experimental psoriasis via the suppression of MAPK/NF-κB/AP-1 phosphorylation in keratinocytes.
    Tang KW; Lin ZC; Wang PW; Alalaiwe A; Tseng CH; Fang JY
    J Dermatol Sci; 2020 Aug; 99(2):90-99. PubMed ID: 32622642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodes.
    Okura I; Kamata M; Asano Y; Mitsui A; Shimizu T; Sato S; Tada Y
    J Dermatol Sci; 2021 May; 102(2):116-125. PubMed ID: 33888401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protectin D1 reduces imiquimod-induced psoriasiform skin inflammation.
    Park KD; Kim N; Kang J; Dhakal H; Kim JY; Jang YH; Lee WJ; Lee SJ; Kim SH
    Int Immunopharmacol; 2021 Sep; 98():107883. PubMed ID: 34153674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
    Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F
    Clin Cancer Res; 2015 Apr; 21(7):1628-38. PubMed ID: 25623213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bromodomain and Extra-Terminal Protein Inhibitor OTX015 Suppresses T Helper Cell Proliferation and Differentiation.
    Hu X; Schewitz-Bowers LP; Lait PJP; Copland DA; Stimpson ML; Li JJ; Liu Y; Dick AD; Lee RWJ; Wei L
    Curr Mol Med; 2018; 18(9):594-601. PubMed ID: 30683020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of keratinocyte necroptosis mediated by RIPK1/RIPK3/MLKL provides a protective effect against psoriatic inflammation.
    Duan X; Liu X; Liu N; Huang Y; Jin Z; Zhang S; Ming Z; Chen H
    Cell Death Dis; 2020 Feb; 11(2):134. PubMed ID: 32075957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models.
    Servidei T; Meco D; Martini M; Battaglia A; Granitto A; Buzzonetti A; Babini G; Massimi L; Tamburrini G; Scambia G; Ruggiero A; Riccardi R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 8-Methyl-pyrrolo[1,2-
    Li Z; Xiao S; Yang Y; Chen C; Lu T; Chen Z; Jiang H; Chen S; Luo C; Zhou B
    J Med Chem; 2020 Apr; 63(8):3956-3975. PubMed ID: 32208600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
    Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
    Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of NLRP3 inflammasome-mediated pyroptosis in macrophage by cycloastragenol contributes to amelioration of imiquimod-induced psoriasis-like skin inflammation in mice.
    Deng G; Chen W; Wang P; Zhan T; Zheng W; Gu Z; Wang X; Ji X; Sun Y
    Int Immunopharmacol; 2019 Sep; 74():105682. PubMed ID: 31203155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diet-induced obesity exacerbates imiquimod-mediated psoriasiform dermatitis in anti-PD-1 antibody-treated mice: Implications for patients being treated with checkpoint inhibitors for cancer.
    Yu S; Wu X; Shi Z; Huynh M; Jena PK; Sheng L; Zhou Y; Han D; Wan YY; Hwang ST
    J Dermatol Sci; 2020 Mar; 97(3):194-200. PubMed ID: 32044178
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Bezdek S; Leng L; Busch H; Mousavi S; Rades D; Dahlke M; Zillikens D; Bucala R; Sadik CD
    Front Immunol; 2018; 9():2262. PubMed ID: 30333830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing γδ T cells.
    Xie XJ; Di TT; Wang Y; Wang MX; Meng YJ; Lin Y; Xu XL; Li P; Zhao JX
    Mol Immunol; 2018 Sep; 101():386-395. PubMed ID: 30064075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of neuropeptide by botulinum toxin improves imiquimod-induced psoriasis-like dermatitis via the regulation of neuroimmune system.
    Amalia SN; Uchiyama A; Baral H; Inoue Y; Yamazaki S; Fujiwara C; Sekiguchi A; Yokoyama Y; Ogino S; Torii R; Hosoi M; Ishikawa O; Motegi SI
    J Dermatol Sci; 2021 Jan; 101(1):58-68. PubMed ID: 33176965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
    Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F
    Oncotarget; 2016 Sep; 7(36):58142-58147. PubMed ID: 27494885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcipotriol and betamethasone dipropionate exhibit different immunomodulatory effects on imiquimod-induced murine psoriasiform dermatitis.
    Takeoka S; Shimizu T; Kamata M; Hau CS; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2020 Feb; 47(2):155-162. PubMed ID: 31762070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation.
    Nadeem A; Al-Harbi NO; Al-Harbi MM; El-Sherbeeny AM; Ahmad SF; Siddiqui N; Ansari MA; Zoheir KM; Attia SM; Al-Hosaini KA; Al-Sharary SD
    Pharmacol Res; 2015 Sep; 99():248-57. PubMed ID: 26149470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18β-Glycyrrhetinic acid induces human HaCaT keratinocytes apoptosis through ROS-mediated PI3K-Akt signaling pathway and ameliorates IMQ-induced psoriasis-like skin lesions in mice.
    Gao J; Guo J; Nong Y; Mo W; Fang H; Mi J; Qi Q; Yang M
    BMC Pharmacol Toxicol; 2020 Jun; 21(1):41. PubMed ID: 32493482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.